Payment overview · 2025
General Payments
$47,428.54
199 reported records · 24 companies
Healthcare provider profile · identity verified
Michael Todd Czarnecki, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · CHATTANOOGA, TN · NPI 1780774083
Verified facts
What the public records show
CMS Open Payments records show Michael Todd Czarnecki, MD received $47,428.54 in general payments during 2025 across 199 reported records.
Grifols USA, LLC accounted for 59.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Adempas, Airsupra, Nucala, Opsumit, Trelegy Ellipta, Uptravi, Winrevair.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPSUMIT as an associated drug or biological on 18955 records involving 8899 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Opsumit by this doctor in 2024.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UPTRAVI as an associated drug or biological on 21562 records involving 9341 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Uptravi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Adempas as an associated drug or biological on 3385 records involving 1868 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Adempas by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUCALA as an associated drug or biological on 100127 records involving 16970 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nucala by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 552 claims for Trelegy Ellipta by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Adempas as an associated drug or biological on 14 records involving 2 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Adempas by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported WINREVAIR as an associated drug or biological on 10378 records involving 3703 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Winrevair by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $28,223.98 | 59.5% | 42 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $13,682.65 | 28.9% | 27 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $3,309.33 | 7.0% | 12 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $344.37 | 0.7% | 20 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $338.54 | 0.7% | 20 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $257.43 | 0.5% | 13 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $190.18 | 0.4% | 15 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $162.39 | 0.3% | 8 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $150.66 | 0.3% | 7 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $122.57 | 0.3% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $122.05 | 0.3% | 5 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $73.12 | 0.1% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $72.44 | 0.1% | 3 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $50.61 | 0.1% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.39 | 0.1% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $45.83 | 0.1% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $43.04 | 0.1% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $39.05 | 0.1% | 2 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $37.64 | 0.1% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $35.98 | 0.1% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.86 | 0.1% | 1 | 2025 |
| Resmed Corp | Unresolved — no canonical attribution shown | $19.34 | 0.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.69 | 0.0% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $17.40 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $32,260.00 | 15 |
| Travel and Lodging | $5,775.96 | 18 |
| Consulting Fee | $4,156.25 | 1 |
| Food and Beverage | $3,613.05 | 161 |
| Education | $1,623.28 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $28,223.98 | 42 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $13,655.32 | 25 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $13,448.08 | 19 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $3,309.33 | 12 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $326.99 | 19 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $198.75 | 12 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $190.18 | 15 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $175.00 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $170.07 | 9 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $162.39 | 8 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $147.34 | 6 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $139.79 | 8 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $122.57 | 5 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $81.81 | 4 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $73.12 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $72.44 | 3 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $58.82 | 2 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $51.79 | 3 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $50.61 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $47.39 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $43.04 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $39.05 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $38.77 | 2 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $37.64 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $37.64 | 1 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $33.71 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $28.94 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $28.94 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $24.86 | 1 | 2025 |
Source payment records
|
|||||
| Orenitram Normalized: orenitram |
Drug | United Therapeutics Corporation | $24.07 | 1 | 2025 |
Source payment records
|
|||||
| Remodulin Normalized: remodulin |
Drug | United Therapeutics Corporation | $24.07 | 1 | 2025 |
Source payment records
|
|||||
| AIRSENSE Normalized: airsense |
Device | Resmed Corp | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| Adempas Normalized: adempas |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.69 | 1 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $17.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Adempas adempas |
2025 | Adempas | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| AIRSUPRA airsupra |
2025 | Airsupra | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUCALA nucala |
2025 | Nucala | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OPSUMIT opsumit |
2025 | Opsumit | 2024 | 124 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 552 | exact normalized | Medicare Part D |
| UPTRAVI uptravi |
2025 | Uptravi | 2024 | 106 | exact normalized | Medicare Part D |
| WINREVAIR winrevair |
2025 | Winrevair | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | OPSUMIT open payments reported associated product |
CMS Open Payments — General Payments 18955 supporting records · 8899 recipient NPIs · example record 1174163978 |
Opsumit · 2024 Exact normalized brand match · 1 Part D row |
124 | 14 |
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | UPTRAVI open payments reported associated product |
CMS Open Payments — General Payments 21562 supporting records · 9341 recipient NPIs · example record 1174163984 |
Uptravi · 2024 Exact normalized brand match · 1 Part D row |
106 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
56 | 17 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Adempas open payments reported associated product |
CMS Open Payments — General Payments 3385 supporting records · 1868 recipient NPIs · example record 1225434673 |
Adempas · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | NUCALA open payments reported associated product |
CMS Open Payments — General Payments 100127 supporting records · 16970 recipient NPIs · example record 1190332378 |
Nucala · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
552 | 171 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | Adempas open payments reported associated product |
CMS Open Payments — General Payments 14 supporting records · 2 recipient NPIs · example record 1237996458 |
Adempas · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | WINREVAIR open payments reported associated product |
CMS Open Payments — General Payments 10378 supporting records · 3703 recipient NPIs · example record 1237992436 |
Winrevair · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 577 | 215 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 552 | 171 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 375 | 71 |
| Montelukast Sodium | Montelukast Sodium | 353 | 125 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 263 | 88 |
| Oxycodone Hcl | Oxycodone Hcl | 181 | 47 |
| Gabapentin | Gabapentin | 146 | 50 |
| Prednisone | Prednisone | 141 | 56 |
| Opsumit | Macitentan | 124 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 117 | 33 |
| Azithromycin | Azithromycin | 113 | 61 |
| Lorazepam | Lorazepam | 111 | 27 |
| Uptravi | Selexipag | 106 | 12 |
| Azelastine Hcl | Azelastine Hcl | 101 | 45 |
| Quetiapine Fumarate | Quetiapine Fumarate | 95 | 20 |
| Methylprednisolone | Methylprednisolone | 88 | 63 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 88 | 23 |
| Spiriva Respimat | Tiotropium Bromide | 86 | 25 |
| Morphine Sulfate Er | Morphine Sulfate | 84 | 19 |
| Alprazolam | Alprazolam | 83 | 18 |
| Xtampza Er | Oxycodone Myristate | 82 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 77 | 26 |
| Breo Ellipta | Fluticasone/Vilanterol | 76 | 22 |
| Roflumilast | Roflumilast | 62 | 17 |
| Famotidine | Famotidine | 61 | 22 |
| Omeprazole | Omeprazole | 58 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 56 | 17 |
| Clonazepam | Clonazepam | 54 | suppressed |
| Furosemide | Furosemide | 54 | 22 |
| Prolastin C | Alpha-1-Proteinase Inhibitor | 49 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 40 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 36 | suppressed |
| Buprenorphine | Buprenorphine | 36 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 33 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 32 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 32 | 13 |
| Eliquis | Apixaban | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 30 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Oxycontin | Oxycodone Hcl | 28 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 27 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 22 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 21 | suppressed |
| Adempas | Riociguat | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | 14 |
| Levofloxacin | Levofloxacin | 20 | 17 |
| Pregabalin | Pregabalin | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 18 |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 18 | suppressed |
| Pirfenidone | Pirfenidone | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Nucala | Mepolizumab | 14 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | 11 |
| Theo-24 | Theophylline Anhydrous | 12 | suppressed |
| Winrevair | Sotatercept-Csrk | 12 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Losartan Potassium | Losartan Potassium | 11 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $47,428.54 · 199 records | Grifols USA, LLC | ABRYSVO, AIRSENSE, AIRSUPRA, AREXVY, Adempas, Arikayce, Brinsupri, COMIRNATY, DUPIXENT, Da Vinci Surgical System, FASENRA, Flexitouch Plus, GLASSIA, Hillrom - Vest System Model 105 Home Care, JASCAYD, NUCALA, Nimbl, OPSUMIT, OPSYNVI, Ohtuvayre, Orenitram, PREVNAR 20, PURIFIED CORTROPHIN GEL, Prolastin-C Liquid, Remodulin, SMARTVEST, Sunosi, TEZSPIRE, TRELEGY ELLIPTA, Tyvaso, UPTRAVI, Vest Therapy Und, WINREVAIR, YUPELRI | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Adempas play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Actelion Pharmaceuticals US, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error